Program
CAB ULA
Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Furthest: phase 3, since Jun 10, 20262 company-led studies, 2 open or runningNext primary completion: Mar 8, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 22 open or running | phase 3since Jun 10, 2026 | Jan 15, 2025 | Mar 8, 2027phase 1 · NCT06786520 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2025First study: phase 1 study in HIV InfectionsFirst studyNCT06786520 · 69 enrolled · United States
- Jun 10, 2026Phase 3 study in HIVPhase 3 reachedNCT07650916 · 564 planned · United States, Argentina, Australia and more
Ahead
- Mar 8, 2027Primary completion: phase 1 study in HIV InfectionsNCT06786520
- Aug 13, 2029Primary completion: phase 3 study in HIVNCT07650916
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07650916HIV · United States, Argentina, Australia and more | 3 | Recruiting | Aug 13, 2029 | 564 |
| NCT06786520HIV Infections · United States | 1 | Active, not recruiting | Mar 8, 2027 | 69 |
How it is read
Names in the registry
- “CAB ULA”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.